Abstract 1195P
Background
Low incidence and heterogeneity of NETs complicates the study of epidemiological and clinical pathways in this population. There is an unmet need for large datasets and BD tools to fill this knowledge gap. Our study aimed to describe the demographic and clinical characteristics of patients with NETs in Spain through the application of BD techniques to EHR.
Methods
This was a retrospective, observational study in adult patients with NETs managed in 5 Spanish centers between 01/01/2014 to 31/12/2019. An unstructured search of free text from EHRs was performed by artificial intelligence (AI) techniques based on SAVANA’s EHRead®, an innovative Natural Language Processing and machine learning system. Patients were included when NET was first identified (Index Date) and classified as `Incident´ or `Prevalent´ if the Index Date was within the study window or not, respectively.
Results
A total of 2,939,309 patients were screened by EHRead and 1,256 NETs cases were found: median age 60y (95% CI 59 - 62), 52% female, 41% with gastroenteropancreatic origin, and 44% were categorized as incident (Table). More than 70% of patients presented symptoms prior to diagnosis and >10% had metastases at diagnosis (>70% were non-resectable). Median time from symptom onset to first diagnosis was 0.6 years (95% CI 0.4 - 0.73). The most frequently detected comorbidities were hypertension (66%), diabetes (35%), asthma (22%), and depression (17%). A previous diagnosis of cancer different from NETs was reported in 21% of cases. Uncommon clinical events included brain metastases (1%) and familial history of NETs (1.1%). Table: 1195P
Classification of patients with NETs
FAS (N=1,256) n (%) | Prevalent (N=700) n (%) | Incident (N=556) n (%) | |
Patients with symptoms before Index Date | 366 (29.1) | 0 (0) | 366 (65.8) |
Primary NET site | |||
Gastroenteropancreatic | 412 (41.4) | 235 (42.7) | 177 (39.7) |
Bronchopulmonary | 171 (17.2) | 81 (14.7) | 90 (20.2) |
Other* | 413 (41.5) | 234 (42.5) | 179 (40.1) |
Classified by surgery at Index Date§ | |||
Thyroidectomy | 9 (0.9) | 3 (0.5) | 6 (1.3) |
Adrenalectomy | 1 (0.1) | 0 (0) | 1 (0.2) |
Other classifications | 1 (0.1) | 1 (0.2) | 0 (0) |
Unclassified NETs | 260 (20.7) | 150 (21.4) | 110 (19.8) |
* Paraganglioma, adrenal gland and medullary thyroid carcinomas and pheochromocytomas§ Within +/-6 months of Index Date
Conclusions
BD Techniques should improve generation of large datasets in low incidence neoplasms and help identify uncommon events. NETs diagnosis is delayed about 6m after symptom onset and comorbidities may influence the choice of treatment.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Content Ed Net (Madrid, Spain)
Legal entity responsible for the study
IPSEN Pharma.
Funding
IPSEN Pharma.
Disclosure
J. Hernando: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13